Skip to main content

Table 6 Infectious outcomes over five years

From: Reduction of early surgical site and other care related infections in 3553 hip fracture patients: lessons learned from the 5-year Safe Hands project

 

Univariable*

Adjusted**

 

Variable and values

n (%) of events

OR (95%CI)

p-value

Area under ROC curve (95%CI)

OR (95%CI)

p-value

ma

Year 1–5

1

13 (2.9%)

      

2

18 (2.2%)

      

3

19 (2.4%)

      

4

9 (1.2%)

      

5

8 (1.1%)

0.78 (0.64–0.94)

0.0086

0.59 (0.53–0.66)

0.78 (0.64–0.94)

0.0092

 

Gender

Female

36 (1.5%)

     

0

Male

31 (2.8%)

1.91 (1.18–3.11)

0.0088

0.58 (0.52–0.64)

1.97 (1.21–3.22)

0.0066

 

Age

65– < 81

22 (1.9%)

     

0

81– < 89

22 (1.7%)

      

89–104

23 (2.0%)

1.01 (0.98–1.04)

0.57

0.52 (0.45–0.59)

1.01 (0.98–1.05)

0.37

 

ASA

I

0 (0.0%)

     

9

II

19 (1.4%)

      

III

43 (2.4%)

      

IV

5 (2.1%)

1.52 (1.05–2.21)

0.027

0.57 (0.52–0.63)

1.41 (0.96–2.06)

0.078

 

Diabetes

Yes

12 (2.1%)

     

0

No

55 (1.8%)

0.88 (0.47–1.65)

0.68

0.51 (0.46–0.56)

0.93 (0.49–1.75)

0.81

 

Hospital length of stay (days)

2- < 9

8 (0.7%)

      

9- < 14

10( 0.8%)

      

14–133

49 (4.3%)

1.11 (1.09–1.13)

 < 0.0001

0.76 (0.70–0.82)

1.11 (1.08–1.13)

 < 0.0001

1

Cognitive failure

Yes

25 (1.9%)

     

1

No

42 (1.9%)

0.99 (0.60–1.63)

0.97

0.50 (0.44–0.56)

1.05 (0.63–1.75)

0.84

 

Time to surgery

 < 36 h

51 (1.7%)

     

2

 > 36 h

16 (2.9%)

1.71 (0.97–3.02)

0.065

0.54 (0.49–0.59)

1.72 (0.97–3.05)

0.064

 

Procedure time, minutes

9– < 57

17 (1.4%)

     

1

57– < 85

14 (1.2%)

      

85–248

35 (2.9%)

1.29 (1.05–1.59)

0.013

0.59 (0.51–0.66)

1.31 (1.07–1.62)

0.0095

 

Pressure ulcers, Norton scale 1–4

1 versus no

8 (4.4%)

2.10 (0.95–4.63)

0.066

 

2.06 (0.93–4.56)

0.076

1732b

2 versus no

2 (1.8%)

0.83 (0.20–3.50)

0.80

 

0.82 (0.19–3.48)

0.79

 

3 versus no

1 (6.7%)

3.28 (0.42–25.71)

0.26

 

3.37 (0.43–26.59)

0.25

 

4 versus no

2 (25.0%)

15.31 (2.98–78.79)

0.0011

0.57 (0.50–0.64)

13.26 (2.53–69.35)

0.0022

 

Urinary tract infection

9 (3.0%)

1.71 (0.84–3.49)

0.14

0.53 (0.48–0.57)

1.68 (0.82–3.43)

0.15

 

Sepsis 0

59 (1.7%)

     

1

Any Sepsis

8 (10.4%)

6.71 (3.09–14.58)

 < 0.0001

0.55 (0.51–0.59)

5.98 (2.73–13.10)

 < 0.0001

 

Pneumonia

8 (3.1%)

1.72 (0.82–3.65)

0.15

0.52 (0.48–0.56)

1.55 (0.73–3.30)

0.25

 

Any type of infection except SSI

21 (2.8%)

1.74 (1.03–2.94)

0.037

0.55 (0.50–0.61)

1.63 (0.97–2.76)

0.068

 

Skin damage

32 (2.6%)

1.81 (1.11–2.95)

0.018

0.57 (0.51–0.63)

1.66 (1.01–2.73)

0.046

30

Before and after one CHXc shower was implemented

27 (2.3%)

     

1

 

39 (1.6%)

0.71 (0.43–1.17)

0.18

0.54 (0.48–0.60)

0.72 (0.44–1.18)

0.19

 

IUCd more than once

18 (4.9%)

3.60 (2.00–6.49)

 < 0.0001

0.61 (0.54–0.68)

3.30 (1.81–6.01)

 < 0.0001

 
  1. P-values, OR and area under ROC curve are based on original values and not on stratified groups
  2. OR is the ratio for the odds of an increase in the predictor of one unit. For procedure time, the odds is given per 30 min
  3. Ma = missing data
  4. b = pressure ulcers, Norton stage 1–4, recorder years 1–3
  5. CXHc = chlorhexidine gluconate
  6. d = in-dwelling catheterisation more than once during hospital stay
  7. *All tests are performed with univariable logistic regression
  8. **Adjusting for gender and age using logistic regression
Back to article page

Antimicrobial Resistance & Infection Control

ISSN: 2047-2994

Contact us